Stocks Health care QURE
NASDAQ · Health careuniQure N.V. (QURE)
uniQure N.V. brought in $20.2M of revenue over the twelve months to September 30, 2026, up 28.0% from a year earlier. It posted a net loss of $232.9M. In fiscal 2025 capital spending exceeded operating cash flow by $178.4M. At September 30, 2026 it held $98.4M in cash against $50.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about uniQure N.V.
- Net worth
- uniQure N.V. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $294.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $16.1M (-40.6% year on year), with a net loss of $199M. Over the 12 months to September 30, 2026: revenue $20.2M, net loss $232.9M.
- Cash flow
- In fiscal 2025 operations used $178M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- uniQure N.V.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What uniQure N.V. does
uniQure N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker QURE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $16.1M | -$199M | -$3.46 | -$178.4M |
| 2024 | $27.1M | -$239.6M | -$4.92 | -$186.1M |
| 2023 | $15.8M | -$308.5M | -$6.47 | -$153.1M |
| 2022 | $106.5M | -$126.8M | -$2.71 | -$162.7M |
| 2021 | $524M | $329.6M | $7.04 | $270.5M |
| 2020 | $37.5M | -$125M | -$2.81 | -$142.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where QURE ranks in Health care
Latest SEC filings
What uniQure N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 40% to $5.2M versus the same quarter last year; diluted EPS -$0.88 versus -$1.38.
- November 4, 2026
- November 2, 2026
- September 29, 2026
- September 2, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 11% to $5.8M versus the same quarter last year; diluted EPS -$1.22 versus -$0.69.
- July 29, 2026
Insider trades
What the people running uniQure N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 30, 2026 | Abi-Saab WalidChief Medical Officer | Received as pay | 18,750 | - |
| July 2, 2026 | Kapusta Matthew CCEO, Managing Director, Director | Exercised options | 21,082 | $408.8K |
| July 2, 2026 | Kapusta Matthew CCEO, Managing Director, Director | Soldpre-planned (10b5-1) | 9,200 | $408.8K |
| July 2, 2026 | Kapusta Matthew CCEO, Managing Director, Director | Soldpre-planned (10b5-1) | 4,282 | $194.5K |
| July 2, 2026 | Kapusta Matthew CCEO, Managing Director, Director | Soldpre-planned (10b5-1) | 7,600 | $348.8K |
| June 30, 2026 | Kaye JackDirector | Exercised options | 4,107 | $152K |
| June 30, 2026 | Kaye JackDirector | Soldpre-planned (10b5-1) | 4,107 | $190.9K |
| June 30, 2026 | Kaye JackDirector | Exercised options | 17,060 | $344.3K |
Who owns QURE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 9.87% | February 17, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 5.7% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 254 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Avoro Capital Advisors LLC | 6,727,777 | +768,182 |
| Jpmorgan Chase & Co | 4,867,755 | +2,030,289 |
| Rtw Investments, LP | 3,941,572 | +1,355,216 |
| State Street Corp | 2,903,825 | +643,313 |
| Aberdeen Group plc | 2,848,117 | -2,458,269 |
| BlackRock, Inc. | 1,877,453 | +143,995 |
| Orbimed Advisors LLC | 1,807,486 | -328,663 |
| Jane Street Group, LLC | 1,610,483 | +974,488 |
| Jennison Associates LLC | 1,561,412 | +327,623 |
| Boxer Capital Management, LLC | 1,503,300 | +841,300 |
| Goldman Sachs Group Inc | 1,475,956 | +212,720 |
| Two Sigma Investments, LP | 1,462,024 | -1,213,847 |
| Two Seas Capital LP | 1,441,410 | +141,410 |
| Fmr LLC | 1,270,068 | -473,740 |
| Mak Capital One LLC | 1,232,051 | +790,846 |
| Mpm Bioimpact LLC | 1,225,855 | -143,376 |
| Morgan Stanley | 1,066,639 | +700,522 |
| Assenagon Asset Management S.A. | 1,027,060 | +880,311 |
| Vestal Point Capital, LP | 935,000 | +576,004 |
| Maverick Capital Ltd | 925,383 | +227,743 |
Insiders
12 insiders reported holding 1,408,807 shares in total, about $32.4M at the last price.
| Holder | Shares |
|---|---|
| Kapusta Matthew CCEO, Managing Director, Director | 519,227 |
| Klemt ChristianChief Financial Officer | 226,581 |
| Abi-Saab WalidChief Medical Officer | 166,985 |
| Potts JeannetteChief Legal Officer | 133,246 |
| O'Keefe KylieChief Customer & Strat Officer | 108,864 |
| Balachandran MadhavanDirector | 43,254 |
| Springhorn Jeremy P.Director | 43,251 |
| Meek David D.Director | 39,747 |
| Post Leonard EDirector | 35,494 |
| Jacques Rachelle SuzanneDirector | 33,903 |
Questions about QURE
What does uniQure N.V. do?
uniQure N.V. is a company in the Health care sector, listed on NASDAQ as QURE. Its shares trade on NASDAQ under the ticker QURE.
What is uniQure N.V.'s net worth?
uniQure N.V. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $294.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is uniQure N.V. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $232.9M on revenue of $20.2M.
How much revenue does uniQure N.V. make?
Over the twelve months to September 30, 2026 uniQure N.V. reported revenue of $20.2M. That is 28.0% more than a year earlier.
When did uniQure N.V. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 6, 2026.
When is uniQure N.V.'s next earnings report?
uniQure N.V.'s next report is expected around March 1, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare QURE with
Follow QURE
Get an email when uniQure N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values uniQure N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.